---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011286"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:36:33.198433+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics faces Nasdaq delisting for minimum bid price; plans hearing

## Summary
- Regained compliance with Nasdaq stockholders' equity requirement on May 14, 2025.
- Received notice of non-compliance with $1.00 minimum bid price; securities subject to delisting.
- Reverse stock split within past year triggers accelerated delisting; suspension possible May 23, 2025.
- Company plans to request hearing by May 21, 2025 to stay suspension pending panel decision.
- No assurance compliance plan will be accepted; delisting risk remains if plan fails.

## SEC filing metadata
- accession: 0001641172-25-011286
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000164117225011286/0001641172-25-011286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000164117225011286/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011286
- JSON: https://secwatch.observer/filing/0001641172-25-011286.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.